辰欣藥業(603367.SH):回購公司股份方案已實施完畢
格隆匯 10 月 22日丨辰欣藥業(603367.SH)公佈,截至2020年9月30日,公司回購股份金額已達到回購方案中的回購金額下限,2020年10月22日,公司召開第三屆董事會第二十二次會議,審議通過了《關於回購公司股份方案實施完畢的議案》,決議決定本次回購期限自本董事會決議之日提前屆滿,此次股份回購實際回購公司股份555.3871萬股,佔公司總股本的比例為1.23%,回購最高價格16.96元/股,回購最低價格14.72元/股,使用資金總額9001.06萬元(含印花税、佣金等交易費用),資金使用已達到回購股份方案規定的最低限額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.